Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery

Cao,Yingxiao; Wang,Fengju; Liu,Zhenbo; Jiao,Baohua

doi:10.3892/etm.2016.3122

Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery

Authors:
- Yingxiao Cao
- Fengju Wang
- Zhenbo Liu
- Baohua Jiao
View Affiliations

Affiliations: Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Neurosurgery, Xingtai People's Hospital Affiliated to Hebei Medical University, Xingtai, Hebei 054031, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/etm.2016.3122
Pages: 1977-1982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary adenomas are benign intracranial endocrine tumors, accounting for ~10% of intracranial tumors. The aim of the present study was to analyze the effects of preoperative treatment with bromocriptine on the surgical treatment and postoperative complications of prolactin‑secreting pituitary adenomas (prolactinomas). Data from 102 patients whose prolactinomas were surgically treated between March 2006 and March 2010 were retrospectively reviewed in the present study. The study group included 54 patients who had been treated preoperatively with bromocriptine. The patients were examined by magnetic resonance imaging (MRI) of the head and coronal computed tomography (CT) scanning, after which the pathological diagnosis of prolactinoma was confirmed. A total of 64 patients underwent total resection surgery through the nose and sphenoid sinus, and 25 patients underwent subtotal resection surgery or excision of a large portion of the tumor, leaving only a small quantity of residual tumor or tumor capsule. Patients were followed up for 1‑9 months using MRI and measurements of serum prolactin levels. Seven patients were lost to follow‑up. The results of the present study demonstrated that patients who were treated with large doses of bromocriptine or used bromocriptine chronically suffered from an increased rate of surgical difficulties and postoperative complications, as compared with the patents who had not been pre‑treated with bromocriptine. In conclusion, oral administration of bromocriptine is important in the treatment of prolactinoma tumors. However, large doses or long‑term use of bromocriptine may increase difficulties in surgery or postoperative complications, and reduce its ability to treat prolactinonas, as it can lead to hardening of the tumor tissue and capsules, and aggravate pituitary stalk adhesions.

View Figures

View References

1	Hirohata T, Ishii Y and Matsuno A: Treatment of pituitary carcinomas and atypical pituitary adenomas: A review. Neurol Med Chir (Tokyo). 54:966–973. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ciric I, Rosenblatt S, Kerr W Jr, Lamarca F, Pierce D and Baumgartner C: Perspective in pituitary adenomas: An end of the century review of tumorigenesis, diagnosis and treatment. Clin Neurosurg. 47:99–111. 2000.PubMed/NCBI
3	Ozgen T, Oruckaptan HH, Ozcan OE and Acikgoz B: Prolactin secreting pituitary adenomas: Analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir (Wien). 141:1287–1294. 1999. View Article : Google Scholar : PubMed/NCBI
4	Landolt AM, Minder H, Osterwalder V and Landolt TA: Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia. 39:625–626. 1983. View Article : Google Scholar : PubMed/NCBI
5	Laws ER Jr, Thorner MO and Vance ML: Bromocriptine therapy for prolactin-secreting pituitary adenomas. Neurosurg Focus. 1:e4discussion 1p following e6. 1996. View Article : Google Scholar : PubMed/NCBI
6	Bergström M, Muhr C, Lundberg PO, Bergström K, Gee AD, Fasth KJ and Långström B: Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: A PET study. J Comput Assist Tomogr. 11:815–819. 1987. View Article : Google Scholar : PubMed/NCBI
7	Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E and Nichol A: Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency. Int J Radiat Oncol Biol Phys. 87:528–533. 2013. View Article : Google Scholar : PubMed/NCBI
8	Elson A, Bovi J, Kaur K, Maas D, Sinson G and Schultz C: Effect of treatment modality on the hypothalamic-pituitary function of patients treated with radiation therapy for pituitary adenomas: Hypothalamic dose and endocrine outcomes. Front Oncol. 4:732014. View Article : Google Scholar : PubMed/NCBI
9	Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, et al: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 65:265–273. 2006. View Article : Google Scholar : PubMed/NCBI
10	Sahoo JP, Kamalanathan S, Parida PK and Pillai V: A giant prolactinoma with nasopharyngeal extension presenting with nasal blockage and epistaxis. BMJ case reports. 2015:2015. View Article : Google Scholar
11	Nakajima T, Tamura T, Kuroki M, Tanaka R and Hayashi H: A case of prolactinoma presenting with CSF rhinorrhea and CSF otorrhea during bromocriptine therapy. No Shinkei Geka. 20:1091–1095. 1992.(In Japanese). PubMed/NCBI
12	Little AS: Repair of cerebrospinal fluid fistula from an invasive skull base prolactinoma using a septal mucosal vascularized flap: Technical case report. J Neurol Surg A Cent Eur Neurosurg. 74(Suppl 1): e50–e53. 2013.PubMed/NCBI
13	Sunil B, Reddy A, Bryant N, Young DW and Ashraf AP: Invasive giant prolactinoma presenting as a nasal polyp. J Pediatr. 162:435. 2013. View Article : Google Scholar : PubMed/NCBI
14	Webster J: Dopamine agonist therapy in hyperprolactinemia. J Reprod Med. 44(Suppl 12): S1105–S1110. 1999.
15	Acharya SV, Gopal RA, Menon PS, Bandgar TR and Shah NS: Giant prolactinoma and effectiveness of medical management. Endocr Pract. 16:42–46. 2010. View Article : Google Scholar : PubMed/NCBI
16	Schettini G, Lombardi G, Merola B, Miletto P, Fariello C, Cirillo S, Fusco R and Lancranjan I: Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas. J Endocrinol Invest. 11:47–51. 1988. View Article : Google Scholar : PubMed/NCBI
17	Mroueh AM and Siler-Khodr TM: Bromocryptine therapy in cases of amenorrhea-galactorrhea. Am J Obstet Gynecol. 127:291–298. 1977. View Article : Google Scholar : PubMed/NCBI
18	Tyson D, Reggiardo D, Sklar C and David R: Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child. 147:1057–1061. 1993. View Article : Google Scholar : PubMed/NCBI
19	Palmeri CM, Petiti JP, del Sosa LV, Gutiérrez S, De Paul AL, Mukdsi JH and Torres AI: Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage. Toxicol Appl Pharmacol. 240:55–65. 2009. View Article : Google Scholar : PubMed/NCBI
20	Liuzzi A, Chiodini PG, Dallabonzana D, Oppizzi G and Verde GG: Medical treatment of pituitary adenomas: Effects on tumor growth. J Endocrinol Invest. 8:273–281. 1985. View Article : Google Scholar : PubMed/NCBI
21	Sharma M, Ambekar S, Sonig A and Nanda A: Factors predicting the development of new onset post-operative Hydrocephalus following trans-sphenoidal surgery for pituitary adenoma. Clin Neurol Neurosurg. 115:1951–1954. 2013. View Article : Google Scholar : PubMed/NCBI
22	Frank G, Pasquini E and Mazzatenta D: Extended transsphenoidal approach. J Neurosurg. 95:917–918. 2001.PubMed/NCBI
23	Cappabianca P, Cavallo LM, Esposito F, De Divitiis O, Messina A and De Divitiis E: Extended endoscopic endonasal approach to the midline skull base: The evolving role of transsphenoidal surgery. Adv Tech Stand Neurosurg. 33:151–199. 2008. View Article : Google Scholar : PubMed/NCBI
24	Grabenbauer GG, Fietkau R, Buchfelder M, Meyer M, Baumann J, Hensen J, Rummelt V, Fahlbusch R and Sauer R: Hormonally inactive hypophyseal adenomas: The results and late sequelae after surgery and radiotherapy. Strahlenther Onkol. 172:193–197. 1996.(In German). PubMed/NCBI
25	Goyal N, Borkar SA, Agrawal D and Mahapatra AK: Pituitary adenoma presenting with cerebrospinal fluid rhinorrhea as the sole symptom. Neurol India. 60:307–308. 2012. View Article : Google Scholar : PubMed/NCBI
26	Perrin G, Stevenaert A and Jouanneau E: Technical aspects and surgical strategy for removal of corticotroph pituitary adenoma. Neurochirurgie. 48:186–214. 2002.(In French). PubMed/NCBI
27	Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M and Mota JI: Endoscopic endonasal transsphenoidal surgery in elderly patients with pituitary adenomas. J Neurosurg. 123:31–38. 2015. View Article : Google Scholar : PubMed/NCBI
28	Berkmann S, Schlaffer S, Nimsky C, Fahlbusch R and Buchfelder M: Intraoperative high-field MRI for transsphenoidal reoperations of nonfunctioning pituitary adenoma. J Neurosurg. 121:1166–1175. 2014. View Article : Google Scholar : PubMed/NCBI
29	Mehta GU, Bakhtian KD and Oldfield EH: Effect of primary empty sella syndrome on pituitary surgery for Cushing's disease. J Neurosurg. 121:518–526. 2014. View Article : Google Scholar : PubMed/NCBI
30	Berker M, Hazer DB, Yucel T, Gurlek A, Cila A, Aldur M and Onerci M: Complications of endoscopic surgery of the pituitary adenomas: Analysis of 570 patients and review of the literature. Pituitary. 15:288–300. 2012. View Article : Google Scholar : PubMed/NCBI
31	Cho JM, Ahn JY, Chang JH and Kim SH: Prevention of cerebrospinal fluid rhinorrhea after transsphenoidal surgery by collagen fleece coated with fibrin sealant without autologous tissue graft or postoperative lumbar drainage. Neurosurgery. 68:130–136. 2011.PubMed/NCBI
32	Lehman NL, Horoupian DS and Harsh GR IV: Synchronous subarachnoid drop metastases from a pituitary adenoma with multiple recurrences. Case report. J Neurosurg. 98:1120–1123. 2003. View Article : Google Scholar : PubMed/NCBI
33	Kim EH, Ku CR, Lee EJ and Kim SH: Extracapsular en bloc resection in pituitary adenoma surgery. Pituitary. 18:397–404. 2015. View Article : Google Scholar : PubMed/NCBI
34	Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF Jr and Pollock BE: Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. 74:147–152. 2010. View Article : Google Scholar : PubMed/NCBI
35	Wollesen F and Bendsen BB: Effect rates of different modalities for treatment of prolactin adenomas. Am J Med. 78:114–122. 1985. View Article : Google Scholar : PubMed/NCBI
36	Dai WD, Liu WH and Zhang DL: One hemodialysis patient with headache, blurred vision and hypotension induced by pituitary prolactinoma. Chin Med J (Engl). 125:2787–2789. 2012.PubMed/NCBI
37	Domingue ME, Devuyst F, Alexopoulou O, Corvilain B and Maiter D: Outcome of prolactinoma after pregnancy and lactation: A study on 73 patients. Clin Endocrinol (Oxf). 80:642–648. 2014. View Article : Google Scholar : PubMed/NCBI
38	Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q and Xu G: Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: A single-center experience with 87 consecutive cases. Eur J Endocrinol. 164:499–504. 2011. View Article : Google Scholar : PubMed/NCBI
39	Landolt AM, Keller PJ, Froesch ER and Mueller J: Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet. 2:657–658. 1982. View Article : Google Scholar : PubMed/NCBI